Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Cryoballoon-to-Pulmonary Vein Occlusion Assessment via Capnography Technique: Where Does Occlusion Testing by End-Tidal CO2 Measurement "Fit" as a Predictor of Long-Term Efficacy?

Pickett RA, Owens K, Landis P, Sara R, Lim HW.

J Atr Fibrillation. 2018 Jun 30;11(1):2055. doi: 10.4022/jafib.2055. eCollection 2018 Jun-Jul.

2.

When Patients Backslide Into Their Back Story: Can Emotional Intelligence Help Emergency Nurses?

Landis P.

J Emerg Nurs. 2018 Nov;44(6):650-651. doi: 10.1016/j.jen.2018.07.015. No abstract available.

PMID:
30415732
3.

Development and Validation of the False Disorder Score: The Focal Scale of the Inventory of Problems.

Viglione DJ, Giromini L, Landis P, McCullaugh JM, Pizitz TD, O'Brien S, Wood S, Connell K, Abramsky A.

J Pers Assess. 2018 Nov 2:1-9. doi: 10.1080/00223891.2018.1492413. [Epub ahead of print]

PMID:
30388903
4.

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.

Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.

PMID:
30309687
5.

Holistic in the Hectic: Family Presence During Resuscitation in the Emergency Department.

Landis P.

Holist Nurs Pract. 2018 May/Jun;32(3):123-124. doi: 10.1097/HNP.0000000000000264.

PMID:
29642125
6.

Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization.

Cheung C, Patel HD, Landis P, Carter HB, Han M.

Urol Oncol. 2018 Apr;36(4):158.e7-158.e12. doi: 10.1016/j.urolonc.2017.12.005. Epub 2017 Dec 26.

PMID:
29288004
7.

Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.

Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, Pavlovich CP.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):339-342. doi: 10.1038/pcan.2017.16. Epub 2017 Apr 18.

8.

Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.

Diniz CP, Landis P, Carter HB, Epstein JI, Mamawala M.

J Urol. 2017 Sep;198(3):608-613. doi: 10.1016/j.juro.2017.03.122. Epub 2017 Mar 24.

PMID:
28347771
10.

The Development of the Inventory of Problems-29: A Brief Self-Administered Measure for Discriminating Bona Fide From Feigned Psychiatric and Cognitive Complaints.

Viglione DJ, Giromini L, Landis P.

J Pers Assess. 2017 Sep-Oct;99(5):534-544. doi: 10.1080/00223891.2016.1233882. Epub 2016 Oct 21.

11.

Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.

Mamawala MM, Rao K, Landis P, Epstein JI, Trock BJ, Tosoian JJ, Pienta KJ, Carter HB.

BJU Int. 2017 Jul;120(1):25-31. doi: 10.1111/bju.13608. Epub 2016 Aug 29.

12.

Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer.

Andreas D, Tosoian JJ, Landis P, Wolf S, Glavaris S, Lotan TL, Schaeffer EM, Sokoll LJ, Ross AE.

Urol Case Rep. 2016 May 26;7:64-6. doi: 10.1016/j.eucr.2016.04.012. eCollection 2016 Jul.

13.

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.

Ma TM, Tosoian JJ, Schaeffer EM, Landis P, Wolf S, Macura KJ, Epstein JI, Mamawala M, Carter HB.

Eur Urol. 2017 Feb;71(2):174-180. doi: 10.1016/j.eururo.2016.05.021. Epub 2016 May 25.

PMID:
27236496
14.

Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.

Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M.

Eur Urol. 2016 Apr;69(4):576-581. doi: 10.1016/j.eururo.2015.09.032. Epub 2015 Oct 9.

PMID:
26456680
15.

A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype.

Zhu G, Liu Z, Epstein JI, Davis C, Christudass CS, Carter HB, Landis P, Zhang H, Chung JY, Hewitt SM, Miller MC, Veltri RW.

Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1864-72. doi: 10.1158/1055-9965.EPI-15-0496. Epub 2015 Sep 24.

16.

Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.

Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB.

Urology. 2015 Nov;86(5):991-5. doi: 10.1016/j.urology.2015.07.039. Epub 2015 Aug 31.

PMID:
26335496
17.

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.

J Clin Oncol. 2015 Oct 20;33(30):3379-85. doi: 10.1200/JCO.2015.62.5764. Epub 2015 Aug 31.

18.

Reveromycin A-Induced Apoptosis in Osteoclasts Is Not Accompanied by Necrosis.

Mead B, Morgan H, Mann-Knowlton A, Tedeschi L, Sloan C, Lang S, Hines C, Gragg M, Stofer J, Riemann K, Derr T, Heller E, Collins D, Landis P, Linna N, Jones D.

J Cell Biochem. 2015 Aug;116(8):1646-57. doi: 10.1002/jcb.25125.

PMID:
25754900
19.

Conditional probability of reclassification in an active surveillance program for prostate cancer.

Alam R, Carter HB, Landis P, Epstein JI, Mamawala M.

J Urol. 2015 Jun;193(6):1950-5. doi: 10.1016/j.juro.2014.12.091. Epub 2015 Jan 6.

20.

Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes.

Dianat SS, Carter HB, Pienta KJ, Schaeffer EM, Landis PK, Epstein JI, Trock BJ, Macura KJ.

Urology. 2015 Jan;85(1):147-53. doi: 10.1016/j.urology.2014.06.085. Epub 2014 Oct 16.

PMID:
25440986
21.

Reclassification rates are higher among African American men than Caucasians on active surveillance.

Sundi D, Faisal FA, Trock BJ, Landis PK, Feng Z, Ross AE, Carter HB, Schaeffer EM.

Urology. 2015 Jan;85(1):155-60. doi: 10.1016/j.urology.2014.08.014. Epub 2014 Oct 14.

22.

Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis.

Cohen JE, Landis P, Trock BJ, Patel HD, Ball MW, Auwaerter PG, Schaeffer E, Carter HB.

J Urol. 2015 Feb;193(2):552-6. doi: 10.1016/j.juro.2014.08.008. Epub 2014 Aug 9.

23.

Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

Patel HD, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB.

J Urol. 2014 Mar;191(3):629-37. doi: 10.1016/j.juro.2013.09.029. Epub 2013 Sep 20.

24.

Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.

Umbehr MH, Platz EA, Peskoe SB, Bhavsar NA, Epstein JI, Landis P, Partin AW, Carter HB.

BJU Int. 2014 Apr;113(4):561-7. doi: 10.1111/bju.12131. Epub 2013 Jun 7.

25.

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

Reese AC, Landis P, Han M, Epstein JI, Carter HB.

J Urol. 2013 Dec;190(6):2033-8. doi: 10.1016/j.juro.2013.05.015. Epub 2013 May 13.

PMID:
23680308
26.

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.

Tosoian JJ, JohnBull E, Trock BJ, Landis P, Epstein JI, Partin AW, Walsh PC, Carter HB.

J Urol. 2013 Oct;190(4):1218-22. doi: 10.1016/j.juro.2013.04.071. Epub 2013 Apr 30.

27.

Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance.

Mullins JK, Bonekamp D, Landis P, Begum H, Partin AW, Epstein JI, Carter HB, Macura KJ.

BJU Int. 2013 Jun;111(7):1037-45. doi: 10.1111/j.1464-410X.2012.11641.x. Epub 2013 Mar 6.

28.

Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.

Han JS, Toll AD, Amin A, Carter HB, Landis P, Lee S, Epstein JI.

Urology. 2012 Oct;80(4):883-8. doi: 10.1016/j.urology.2012.05.045. Epub 2012 Aug 22.

29.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

J Urol. 2012 Oct;188(4):1131-6. doi: 10.1016/j.juro.2012.06.009. Epub 2012 Aug 15.

30.

Pharmacokinetic comparison of a single oral dose of polymorph form i versus form V capsules of the antiorthopoxvirus compound ST-246 in human volunteers.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Bolken TC, Jordan R, Jones KF, Marbury T, Lichtenstein I, Pickens M, Corrado M, Landis P, Clarke JM, Frimm AM, Hruby DE.

Antimicrob Agents Chemother. 2012 Jul;56(7):3582-6. doi: 10.1128/AAC.06090-11. Epub 2012 Apr 23.

31.

Design, synthesis and structure-activity relationship of N-substituted tropane muscarinic acetylcholine receptor antagonists.

Lainé DI, Yan H, Xie H, Davis RS, Dufour J, Widdowson KL, Palovich MR, Wan Z, Foley JJ, Schmidt DB, Hunsberger GE, Burman M, Bacon AM, Webb EF, Luttmann MA, Salmon M, Sarau HM, Umbrecht ST, Landis PS, Peck BJ, Busch-Petersen J.

Bioorg Med Chem Lett. 2012 May 1;22(9):3366-9. doi: 10.1016/j.bmcl.2012.02.015. Epub 2012 Feb 15.

PMID:
22460029
32.

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

BJU Int. 2012 Sep;110(5):651-7. doi: 10.1111/j.1464-410X.2011.10875.x. Epub 2012 Jan 30.

33.

Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.

Ko JS, Landis P, Carter HB, Partin AW.

BJU Int. 2011 Dec;108(11):1739-42. doi: 10.1111/j.1464-410X.2011.10223.x. Epub 2011 Jul 8.

34.

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, Walsh PC, Carter HB.

J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.

PMID:
21464416
35.

Repeat prostate biopsies predict location of index cancer in an active surveillance cohort.

Tseng KS, Landis P, Brimo F, Partin AW, Epstein JI, Carter HB.

BJU Int. 2011 Nov;108(9):1415-20. doi: 10.1111/j.1464-410X.2011.10176.x. Epub 2011 Mar 28.

36.

ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.

Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW.

Urology. 2011 Mar;77(3):763.e1-6. doi: 10.1016/j.urology.2010.07.526. Epub 2011 Jan 8.

37.

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC.

J Clin Oncol. 2010 Jun 10;28(17):2810-6. doi: 10.1200/JCO.2009.25.7311. Epub 2010 May 3.

PMID:
20439642
38.

Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects.

Jordan R, Chinsangaram J, Bolken TC, Tyavanagimatt SR, Tien D, Jones KF, Frimm A, Corrado ML, Pickens M, Landis P, Clarke J, Marbury TC, Hruby DE.

Antimicrob Agents Chemother. 2010 Jun;54(6):2560-6. doi: 10.1128/AAC.01689-09. Epub 2010 Apr 12.

39.

Risk stratification of men choosing surveillance for low risk prostate cancer.

Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB.

J Urol. 2010 May;183(5):1779-85. doi: 10.1016/j.juro.2010.01.001. Epub 2010 Mar 20.

40.

Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ.

J Urol. 2010 Feb;183(2):534-8. doi: 10.1016/j.juro.2009.10.003. Epub 2009 Dec 14.

PMID:
20006883
41.

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.

Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW.

Clin Cancer Res. 2009 Dec 1;15(23):7316-21. doi: 10.1158/1078-0432.CCR-09-1263. Epub 2009 Nov 24.

42.

The Optimal Application of Prostate-Specific Antigen (PSA) Velocity to Predict High-Risk Disease.

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter BH.

Eur Urol. 2008 Nov;54(5):978-979. Epub 2008 Aug 3. No abstract available.

43.

Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance.

Fujita K, Landis P, McNeil BK, Pavlovich CP.

J Urol. 2009 Dec;182(6):2664-9. doi: 10.1016/j.juro.2009.08.044.

PMID:
19836757
44.

DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme.

Isharwal S, Makarov DV, Carter HB, Epstein JI, Partin AW, Landis P, Marlow C, Veltri RW.

BJU Int. 2010 Feb;105(3):329-33. doi: 10.1111/j.1464-410X.2009.08791.x. Epub 2009 Aug 12.

45.

Prostate specific antigen testing among the elderly--when to stop?

Schaeffer EM, Carter HB, Kettermann A, Loeb S, Ferrucci L, Landis P, Trock BJ, Metter EJ.

J Urol. 2009 Apr;181(4):1606-14; discussion 1613-4. doi: 10.1016/j.juro.2008.11.117. Epub 2009 Feb 25.

46.

PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.

Loeb S, Kettermann A, Ferrucci L, Landis P, Metter EJ, Carter HB.

Eur Urol. 2008 Nov;54(5):1073-80. doi: 10.1016/j.eururo.2008.06.076. Epub 2008 Jul 2.

47.

Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.

Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI.

J Urol. 2008 Mar;179(3):901-4; discussion 904-5. doi: 10.1016/j.juro.2007.10.062. Epub 2008 Jan 22.

48.
49.
50.

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.

Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI.

J Urol. 2007 Dec;178(6):2359-64; discussion 2364-5. Epub 2007 Oct 22.

Supplemental Content

Loading ...
Support Center